Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update